UBS AM
SRNE

UBS AM’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

UBS AM’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-266,443
Closed -$236K – 2750
2022
Q4 		$236K Hold
266,443
– – ﹤0.01% 2400
2022
Q3 		$418K Hold
266,443
– – ﹤0.01% 2406
2022
Q2 		$536K Buy
266,443
+10,100
+4% +$17.5K ﹤0.01% 2279
2022
Q1 		$597K Hold
256,343
– – ﹤0.01% 2391
2021
Q4 		$1.19M Sell
256,343
-45,555
-15% -$283K ﹤0.01% 2117
2021
Q3 		$2.3M Sell
301,898
-8,403
-3% -$71.3K ﹤0.01% 1772
2021
Q2 		$3.01M Buy
310,301
+81,402
+36% +$648K ﹤0.01% 1661
2021
Q1 		$1.89M Buy
228,899
+8,883
+4% +$93.8K ﹤0.01% 1764
2020
Q4 		$1.5M Buy
220,016
+98,990
+82% +$795K ﹤0.01% 1800
2020
Q3 		$1.35M Buy
121,026
+5,543
+5% +$50.7K ﹤0.01% 1717
2020
Q2 		$725K Buy
+115,483
New +$442K ﹤0.01% 1940
2019
Q4 		– Sell
-48,801
Closed -$104K – 2908
2019
Q3 		$104K Sell
48,801
-4,095
-8% -$9.54K ﹤0.01% 2658
2019
Q2 		$141K Buy
52,896
+14,943
+39% +$53.8K ﹤0.01% 2608
2019
Q1 		$180K Buy
37,953
+3,900
+11% +$10.2K ﹤0.01% 2490
2018
Q4 		$81.7K Buy
34,053
+12,453
+58% +$40.7K ﹤0.01% 2535
2018
Q3 		$95K Hold
21,600
– – ﹤0.01% 2531
2018
Q2 		$156K Buy
+21,600
New +$147K ﹤0.01% 2523

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

UBS AM's SRNE Position: Q1 2023 in Review

UBS AM sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 266,443 shares — an estimated $236K sold.

UBS AM first reported a position in SRNE in Q2 2018 and held it in 17 quarters. The position peaked at $3.01M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • UBS AM reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • UBS AM sold 266,443 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $236K.
  • UBS AM first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 17 quarters.
  • UBS AM's Sorrento Therapeutics, Inc. position peaked at $3.01M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.